<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Harman T</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> T-type Ca&lt;sup>2+&lt;/sup> channels (Ca&lt;sub>v&lt;/sub>3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical entities which act at these ion channels. A number of synthetic cannabinoid receptor agonists (SCRAs) have been found to exhibit activity at T-type channels, suggesting that cannabinoids may provide convenient chemical scaffolds on which to design novel Ca&lt;sub>v&lt;/sub>3 inhibitors. However, activity at cannabinoid type 1 (CB&lt;sub>1&lt;/sub>) receptors can be problematic because of central and peripheral toxicities associated with potent SCRAs. The putative SCRA MEPIRAPIM and its analogues were recently identified as Ca&lt;</pubmed_abstract><journal>Frontiers in physiology</journal><pagination>1086243</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10110893</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy.</pubmed_title><pmcid>PMC10110893</pmcid><pubmed_authors>Howland JG</pubmed_authors><pubmed_authors>Snutch TP</pubmed_authors><pubmed_authors>Ametovski A</pubmed_authors><pubmed_authors>Banister SD</pubmed_authors><pubmed_authors>Greba Q</pubmed_authors><pubmed_authors>Harman T</pubmed_authors><pubmed_authors>Arnold JC</pubmed_authors><pubmed_authors>Kevin RC</pubmed_authors><pubmed_authors>Udoh M</pubmed_authors><pubmed_authors>McElroy DL</pubmed_authors><pubmed_authors>Anderson LL</pubmed_authors><pubmed_authors>Doohan PT</pubmed_authors><pubmed_authors>Markham J</pubmed_authors><pubmed_authors>Bladen C</pubmed_authors><pubmed_authors>McGregor IS</pubmed_authors><pubmed_authors>Laprairie RB</pubmed_authors></additional><is_claimable>false</is_claimable><name>MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy.</name><description>&lt;b>Background:&lt;/b> T-type Ca&lt;sup>2+&lt;/sup> channels (Ca&lt;sub>v&lt;/sub>3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical entities which act at these ion channels. A number of synthetic cannabinoid receptor agonists (SCRAs) have been found to exhibit activity at T-type channels, suggesting that cannabinoids may provide convenient chemical scaffolds on which to design novel Ca&lt;sub>v&lt;/sub>3 inhibitors. However, activity at cannabinoid type 1 (CB&lt;sub>1&lt;/sub>) receptors can be problematic because of central and peripheral toxicities associated with potent SCRAs. The putative SCRA MEPIRAPIM and its analogues were recently identified as Ca&lt;</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-05-28T17:58:51.603Z</modification><creation>2024-12-03T15:59:54.595Z</creation></dates><accession>S-EPMC10110893</accession><cross_references><pubmed>37082241</pubmed><doi>10.3389/fphys.2023.1086243</doi></cross_references></HashMap>